Gonadorelin
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Synthetic GnRH — the same 10-amino-acid decapeptide your hypothalamus secretes. Gonadorelin is the GnRH molecule itself, provided exogenously. It acts one step up from HCG (which is at the testicles) and one step down from Kisspeptin (which is upstream of GnRH).
What does it do in my body?
- Binds GnRH receptors on pituitary gonadotrophs.
- Triggers LH + FSH release.
- Critical: must be dosed pulsatile, not constant. Constant GnRH exposure desensitizes the pituitary (this is actually how GnRH agonists work as chemical castration in prostate cancer — the opposite effect). For HPG restoration, gonadorelin must mimic the natural pulsatile rhythm — typically multiple small injections per day or via a pump.
How can it help me?
- Best fit: GnRH-to-pituitary signal insufficient; also used as a TRT-adjuvant replacement for HCG when HCG access is limited
- Where the science stands: Strong for true pulses: hourly pulses restore LH/FSH while continuous GnRH shuts them down; long-term pulsatile low-dose GnRH induced puberty in men with GnRH deficiency. Weak for twice-weekly TRT-adjuvant use: mostly clinic experience, no controlled trials
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
- Generally well-tolerated.
- Constant (non-pulsatile) dosing produces paradoxical pituitary desensitization — the most common protocol error.
Regulatory status: Gonadorelin has a genuine clinical/diagnostic pedigree, not just a research-chem history. It has been used historically as a formal FDA diagnostic agent — the GnRH stimulation test, a real clinical procedure used to assess pituitary function. It is available through compounding pharmacies for HPG-axis use. It is prohibited by WADA in male athletes as an LH-releasing factor (Prohibited List, class S2, verified 2026-10-01). Gonadorelin was previously FDA-approved both as a diagnostic agent and for pulsatile pump therapy; those branded products are no longer marketed in the US, and gonadorelin today comes mostly from compounding pharmacies. Branded hCG remains prescription-available.
For contrast, worth knowing: Triptorelin is a related decapeptide (a single D-Trp⁶ substitution vs. native GnRH) that functions as a GnRH superagonist with roughly 50–100× GnRH-receptor affinity and a long-acting profile — used for gonadal suppression (prostate cancer, endometriosis), the opposite clinical goal to gonadorelin’s restoration use here.
Part 1 — How to reconstitute it
What's used: bacteriostatic water (sterile, preserved water the powder is mixed with) and a separate, larger reconstitution syringe used only for mixing — not the small syringe used for administration.
The exact bacteriostatic-water volume and resulting concentration for Gonadorelin are covered in the dosing notes and the deeper-science view. The right volume depends on the vial size.
How it's mixed
- The vial is tilted and the bacteriostatic water is added slowly down the inside glass wall — not squirted straight onto the powder.
- It is swirled gently to dissolve. It is never shaken — shaking can damage the peptide.
- The reconstituted vial is stored refrigerated and out of light.
- Reconstituted peptides are commonly used within a few weeks, inside the beyond-use window the source specifies — that window varies by peptide.
The free reconstitution calculator does the concentration math for any vial size and water volume, including the equivalent units on an insulin syringe.
Part 2 — Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
Administration as reported. Reported practice is subcutaneous administration (into the fat just under the skin) using a 0.3 mL U-100 insulin syringe, with sites rotated.
- Pulsatile dosing is non-negotiable. Constant exposure desensitizes the receptor and produces the opposite effect.
- Community-typical TRT-adjuvant dose: 100–300 mcg SubQ per injection. Schedules vary widely, from 2–3× daily in some protocols to the several-times-weekly schedule many TRT clinics use. Neither has controlled-trial backing; the only schedule with strong evidence is pump-delivered pulses every ~1–2 hours.
- Half-life is short (minutes range) — this is why it must be pulsatile; a single daily bolus produces a brief spike and nothing else.
- Reconstitution: typical 5 mg vial + 5 mL bacteriostatic water = 1 mg/mL = 100 mcg per 10 units on a U-100 insulin syringe.
What should I avoid combining — and what's synergistic?
Gonadorelin doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
Wiki article (split 2026-07-16 from the retired HPGA-restoration cluster article, per-compound doctrine). Built from. Cross-links: Enclomiphene · HCG (Human Chorionic Gonadotropin) · Kisspeptin. The broader “which lever matches your bloodwork” decision framework — the HPG-axis mechanism map, the decision algorithm, and the TRT-vs-restoration big picture — now lives in the Peptides 101 article HPGA Restoration: Choosing the Right Lever.
| Class | Synthetic GnRH — the same 10-amino-acid decapeptide the hypothalamus secretes |
| Mechanism (one line) | Binds GnRH receptors on pituitary gonadotrophs → triggers LH + FSH release; must be dosed pulsatile, not constant, or the pituitary desensitizes |
| Acts at | Pituitary (gonadotroph cells) — one step up from HCG (which acts at the testes), one step down from Kisspeptin (upstream of GnRH) |
| Route / frequency | Proven format: a pump delivering a pulse every ~60–120 min. Common TRT-clinic format: SubQ injections several times a week (weak evidence, see below) |
| Best-fit use case | GnRH-to-pituitary signal insufficient; also used as a TRT-adjuvant replacement for HCG when HCG access is limited |
| Evidence base | Strong for true pulses: hourly pulses restore LH/FSH while continuous GnRH shuts them down; long-term pulsatile low-dose GnRH induced puberty in men with GnRH deficiency. Weak for twice-weekly TRT-adjuvant use: mostly clinic experience, no controlled trials |
| Regulatory status | Real clinical pathway distinct from typical research-chem peptides — used historically as an FDA diagnostic agent (the GnRH stimulation test); available via compounding pharmacies |
What it is
Synthetic GnRH — the same 10-amino-acid decapeptide your hypothalamus secretes. Gonadorelin is the GnRH molecule itself, provided exogenously. It acts one step up from HCG (which is at the testicles) and one step down from Kisspeptin (which is upstream of GnRH).
How it works
- Binds GnRH receptors on pituitary gonadotrophs.
- Triggers LH + FSH release.
- Critical: must be dosed pulsatile, not constant. Constant GnRH exposure desensitizes the pituitary (this is actually how GnRH agonists work as chemical castration in prostate cancer — the opposite effect). For HPG restoration, gonadorelin must mimic the natural pulsatile rhythm — typically multiple small injections per day or via a pump.
What the research shows
- Long-established pharmacology — gonadorelin = GnRH; the mechanism is textbook endocrinology.
- Timing decides everything. In the classic primate study, continuous GnRH failed to sustain LH/FSH release and could shut it down, while once-hourly pulses restored normal secretion. That single finding explains both of gonadorelin’s lives: pulses restore the axis, while constant exposure suppresses it, which is exactly how long-acting GnRH agonists like leuprolide are used to shut the axis down.
- Pump therapy works. Long-term pulsatile low-dose GnRH induced puberty and testicular function in men whose hypothalamus doesn’t make GnRH. Pump therapy (a pulse every ~60–120 minutes, around the clock) remains the established use, restoring both hormones and fertility in hypothalamic hypogonadism (Kallmann syndrome, idiopathic hypogonadotropic hypogonadism).
- The TRT-adjuvant use is a different animal. Many men on TRT now inject gonadorelin a few times a week to keep the testes stimulated and preserve size and function. The practice grew after compounded hCG largely disappeared in 2020, when hCG was moved to the biologics pathway (see HCG (Human Chorionic Gonadotropin)). The problem is the half-life: a twice-weekly dose gives a brief LH spike that clears within hours, nothing like the hourly pulses used in pump therapy. Controlled evidence that this schedule preserves testicular size or fertility is limited; most of what’s described as standard practice comes from clinic experience, not trials. For testicular preservation on TRT, hCG remains the better-studied option.
- What users report: mixed. Some men on TRT describe fuller testes and better libido with gonadorelin; others notice little difference from TRT alone. Some clinics still prefer branded hCG when cost allows.
Gonadorelin vs. kisspeptin. Both push the top of the HPG axis, at different rungs. Kisspeptin sits one step above GnRH and works through the body’s own GnRH neurons, so the natural pulse pattern is preserved, but it needs a working hypothalamus. Gonadorelin is GnRH and bypasses the hypothalamus, so it works even when the hypothalamus can’t make GnRH, but only as true pulses. Both fade with too much exposure: gonadorelin through pituitary desensitization under continuous delivery, kisspeptin through tachyphylaxis with frequent dosing. (Source:, all citations verified.)
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
- Pulsatile dosing is non-negotiable. Constant exposure desensitizes the receptor and produces the opposite effect.
- Community-typical TRT-adjuvant dose: 100–300 mcg SubQ per injection. Schedules vary widely, from 2–3× daily in some protocols to the several-times-weekly schedule many TRT clinics use. Neither has controlled-trial backing; the only schedule with strong evidence is pump-delivered pulses every ~1–2 hours.
- Half-life is short (minutes range) — this is why it must be pulsatile; a single daily bolus produces a brief spike and nothing else.
- Reconstitution: typical 5 mg vial + 5 mL bacteriostatic water = 1 mg/mL = 100 mcg per 10 units on a U-100 insulin syringe.
Side effects & management
- Generally well-tolerated.
- Constant (non-pulsatile) dosing produces paradoxical pituitary desensitization — the most common protocol error.
Regulatory status
Gonadorelin has a genuine clinical/diagnostic pedigree, not just a research-chem history. It has been used historically as a formal FDA diagnostic agent — the GnRH stimulation test, a real clinical procedure used to assess pituitary function. It is available through compounding pharmacies for HPG-axis use. It is prohibited by WADA in male athletes as an LH-releasing factor (Prohibited List, class S2, verified 2026-10-01). Gonadorelin was previously FDA-approved both as a diagnostic agent and for pulsatile pump therapy; those branded products are no longer marketed in the US, and gonadorelin today comes mostly from compounding pharmacies. Branded hCG remains prescription-available.
For contrast, worth knowing: Triptorelin is a related decapeptide (a single D-Trp⁶ substitution vs. native GnRH) that functions as a GnRH superagonist with roughly 50–100× GnRH-receptor affinity and a long-acting profile — used for gonadal suppression (prostate cancer, endometriosis), the opposite clinical goal to gonadorelin’s restoration use here.
Technical & analytical reference (chemistry & QC)
Verified identity values (PubChem / CAS; identity confirmed, not from analytical capture).
| Field | Value |
|---|---|
| Formula | C55H75N17O13 |
| Avg MW | 1182.31 |
| CAS | 33515-09-2 |
| Sequence | pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 |
| PubChem CID | 638793 |
Native GnRH decapeptide; identity by HPLC-UV + LC-MS against the 1182.31 average mass.
Citation leads (PeptideBiologix; until confirmed): PeptideBiologix analytical page for Gonadorelin (raw capture ) — method/PK detail only; identity values above are from PubChem/CAS, not the capture.
Sources
- the 4-tool cascade-failure-point map, gonadorelin mechanism, pulsatile-dosing requirement.
- kisspeptin vs gonadorelin evidence review (Pruski Substack, 2026-10-01), all citations verified: pulse-vs-continuous biology, TRT twice-weekly half-life mismatch, hCG 2020 biologics transition, WADA status.
- Belchetz 1978 (Science) 100883 — continuous vs intermittent GnRH in rhesus monkeys: continuous suppresses, hourly pulses restore.
- Hoffman & Crowley 1982 (NEJM) 6813732 — long-term pulsatile low-dose GnRH induces puberty in GnRH-deficient men.
triptorelin.md— analytical/method-detail raw captures ( pending).- Established endocrinology: HPG axis cascade, GnRH agonist vs. superagonist pharmacology.
Related: Enclomiphene · HCG (Human Chorionic Gonadotropin) · Kisspeptin.
Sources & references
- the 4-tool cascade-failure-point map, gonadorelin mechanism, pulsatile-dosing requirement.
- kisspeptin vs gonadorelin evidence review (Pruski Substack, 2026-10-01), all citations verified: pulse-vs-continuous biology, TRT twice-weekly half-life mismatch, hCG 2020 biologics transition, WADA status.
- Belchetz 1978 (Science) 100883 — continuous vs intermittent GnRH in rhesus monkeys: continuous suppresses, hourly pulses restore.
- Hoffman & Crowley 1982 (NEJM) 6813732 — long-term pulsatile low-dose GnRH induces puberty in GnRH-deficient men.
triptorelin.md— analytical/method-detail raw captures ( pending).- Established endocrinology: HPG axis cascade, GnRH agonist vs. superagonist pharmacology.
Related: Enclomiphene · HCG (Human Chorionic Gonadotropin) · Kisspeptin.